Results of an investigator-initiated single-blind split-face comparison of photodynamic therapy and 5% imiquimod cream for the treatment of actinic keratoses

Dermatologic Surgery

Volumn 38, Issue 5, 2012, Pages 722-727

  Hadley, Jason ^a   Tristani Firouzi, Payam ^b   Hull, Christopher ^a   Florell, Scott ^a   Cotter, Murray ^c   Hadley, Michael ^a  

^a McKay Dee Dermatology   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c Dermatology Associates of N Michigan   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; IMIQUIMOD;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; AMINOQUINOLINES; FACIAL DERMATOSES; HUMANS; INTERFERON INDUCERS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; QUALITY OF LIFE; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84860649763     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2012.02340.x     Document Type: Article

References (19)

1. Lober BA, Lober CW, Accola J,. Actinic keratosis is squamous cell carcinoma. J Am Acad Dermatol 2000; 43: 881-2.
2. Criscione VD, Weinstock MA, Naylor MF, Luque C, et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009; 115: 2523-30.
3. Graceway Pharmaceuticals. Aldara package insert. Graceway Pharmaceuticals: Bristol, TN, 2007.
4. Czelusta AJ, Evans T, Arany I, Tyring SK,. A guide to immunotherapy of genital warts: focus on interferon and imiquimod. BioDrugs 1999; 11: 319-32. (Pubitemid 29235062)
5. Smith K, Hamza S, Germain M, Skelton H,. Does imiquimod histologically rejuvenate ultraviolet radiation-damaged skin? Dermatol Surg 2007; 33: 1419-28; discussion 28-9. (Pubitemid 350212674)
6. Kalka K, Merk H, Mukhtar H,. Photodynamic therapy in dermatology. J Am Acad Dermatol 2000; 42: 389-413; quiz 4-6.
7. Dragieva G, Hafner J, Dummer R, Schmid-Grendelmeier P, et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation 2004; 77: 115-21. (Pubitemid 38116882)
8. Finlay AY,. Quality of life measurement in dermatology: a practical guide. Br J Dermatol 1997; 136: 305-14. (Pubitemid 27105848)
9. Hongbo Y, Thomas CL, Harrison MA, Salek MS, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005; 125: 659-64.
10. Gebauer K, Shumack S, Cowen PS,. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial. Br J Dermatol 2009; 161: 897-903.
11. Jeffes EW, McCullough JL, Weinstein GD, Fergin PE, et al. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study. Arch Dermatol 1997; 133: 727-32. (Pubitemid 27263706)
12. Jorizzo J, Dinehart S, Matheson R, Moore JK, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007; 57: 265-8. (Pubitemid 47048863)
13. Radakovic-Fijan S, Blecha-Thalhammer U, Kittler H, Honigsmann H, et al. Efficacy of 3 different light doses in the treatment of actinic keratosis with 5-aminolevulinic acid photodynamic therapy: a randomized, observer-blinded, intrapatient, comparison study. J Am Acad Dermatol 2005; 53: 823-7. (Pubitemid 41501368)
14. Sotiriou E, Apalla Z, Maliamani F, Zaparas N, et al. Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy versus 5% imiquimod cream for actinic keratoses on the upper extremities. J Eur Acad Dermatol Venereol 2009; 23: 1061-5.
15. Talghini S, Halimi M, Baybordi H,. Expression of P27, Ki67 and P53 in squamous cell carcinoma, actinic keratosis and Bowen disease. Pak J Biol Sci 2009; 12: 929-33.
16. Sutter C, Wersin R, Varnai M, Friemann J,. [Elevated p53 protein expression in normal and neoplastic light-exposed epidermis]. Verh Dtsch Ges Pathol 1994; 78: 246-51.
17. Bolognia J, Jorizzo JL, Rapini RP,. Dermatology (2nd ed). Mosby: Edinburgh, 2007.
18. Ulrich C, Bichel J, Euvrard S, Guidi B, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007; 157 (Suppl 2): 25-31. (Pubitemid 350179626)
19. Hanke CW, Beer KR, Stockfleth E, Wu J, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol 2010; 62: 573-81.